HanAll Biopharma set to expand presence in Asia with autoimmune treatment
A HanAll Biopharma researcher conducts experiments in this photo provided by the company, Monday. Courtesy of HanAll BiopharmaBy Baek Byung-yeulLocal biotech company HanAll Biopharma is seeking to expand its presence in Asia, as the company is set to begin Phase 3 clinical testing of its autoimmune disease treatment candidate in Japan in the second half of 2022, the company said Monday.“HanAll plans to deliver innovative therapy to patients around the world by launching a Phase 3 clinical trial in MG in Japan in the second half of this year. As HanAll holds the rights to batoclimab outside its region including Korea, Japan and Oceania, the company's aim to introduce a global blockbuster into the market is not building castles in the air,” a company spokesperson said.MG stands for myasthenia gravis. It is a rare, severe autoimmune disorder of the neuromuscular junction characterized by weakness in muscles. In the U.S. around 65,000 patients are suffering from the disease.The current therapies are limited due to inadequate efficacy, safety issues and limited access to the t
